Chemotherapy-Induced Peripheral Neuropathy (CIPN) can occur when chemo-drugs used to treat cancer or other malignancies damage peripheral nerves with subsequent nerve pain. CIPN can last for weeks, months, years after treatment and can predispose to future nerve damage by other causes, such as diabetes. This often debilitating condition causes many patients to choose not to complete their full course of chemotherapy, thus affecting outcome.
Prevents nerve damage and subsequent nerve pain caused by toxic impact of chemo
Doesn’t enter the bloodstream and risk side effects
Topical relief that acts directly at point of pain, itch or irritation.
Avoids addictive opioids
to deal with pain
Reduces chronic itching and inflammation
Can be used as pretreatment to prevent neurotoxic damage to sensory nerves
TRPblue is developing topical therapeutics that can potently target two TRP ion channels in the skin for effective prevention and treatment of pain, itch and skin inflammation due to Chemotherapy-Induced Peripheral Neuropathy.
Our proprietary lead compound inhibits ion channels TRPV4 and TRPA1, protecting skin-innervating nerve cells and skin cells from toxic calcium overload. This prevents nerve damage and nerve pain and attenuates irritation and inflammation.
Partner with Us
TRPblue is seeking partners and investors as we rapidly advance our clinical candidate toward proof of concept Phase I clinical trials.
We have been supported by MedBlue Incubator, NC Biotech and the National Institutes of Health to develop our innovative and patented technology.